<DOC>
	<DOCNO>NCT02153632</DOCNO>
	<brief_summary>Amantadine HCl ER use many year treatment Parkinson 's disease . It report literature effectively treat motor complication levodopa , especially dyskinesia , must give 2 4 time day . The purpose multi-center , randomize , double-blind , parallel-group , 26 week study compare efficacy safety two different dose level Amantadine Extended Release Tablets placebo treatment levodopa induce dyskinesia patient Parkinson 's disease . The dose give day morning amantadine concentration maintain throughout day treat levodopa induce dyskinesia , low night , potentially reduce negative impact amantadine sleep .</brief_summary>
	<brief_title>Efficacy Safety Amantadine HCl Extended Release Tablets Parkinson 's Disease Subjects With Levodopa-Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Signed IRB/IEC informed consent form . Idiopathic Parkinson 's disease per UK Parkinson 's Disease Society Brain Bank criterion . Male female 30 85 year old . Levodopa induce , predictable peakeffect dyskinesia consider problematic and/or disabling . Screening serum creatinine level within normal range On stable dos oral antiParkinson 's medication , include levodopa preparation , 30 day willing remain dos throughout trial . The subject/caregiver must demonstrate ability complete accurate home diary base train evaluation screen period . Secondary parkinsonian syndrome , vascular , postinflammatory , druginduced , neoplastic posttraumatic parkinsonism atypical parkinsonian syndrome ( e.g. , Progressive Supranuclear Palsy , MultiSystem Atrophy , etc . ) ; Use amantadine within 14 day study start , previously adverse event amantadine Currently take neuroleptic atypical antipsychotic agent , acetylcholinesterase inhibitor , apomorphine , rimantadine , memantine dextromethorphan quinidine use combination treat dyskinesia . History neurosurgical intervention treat Parkinson 's disease ( i.e . pallidotomy implanted deep brain stimulator ) Any medical condition past medical history would increase risk exposure Amantadine HCl Extended Release Tablets interfere safety efficacy evaluation . History cancer within 5 year screen following exception : adequately treat nonmelanomatous skin cancer , localize bladder cancer , nonmetastatic prostate cancer situ cervical cancer . History current diagnosis schizophrenia bipolar disorder ; Inadequately treat Major Depressive Disorder . Subjects stable dos selective serotonin reuptake inhibitor ( SSRIs ) serotoninnorepinephrine reuptake inhibitor ( SNRIs ) eligible study ; Is imminent risk suicide suicide attempt within 6 month screen History current diagnosis Impulse Control Disorder Calculated plasma creatinine clearance &lt; 60 mL/min screen History currently follow clinically significant condition , cardiovascular , respiratory , renal , hepatic , gastrointestinal disease Any clinically significant vital sign , ECG , laboratory abnormality ; A positive test HIV antibody history HIV ; hepatitis B surface antigen unless positive test follow recent ( &lt; 28 day ) vaccination hepatitis B ; hepatitis C antibody ; A positive urine drug test . Pregnant breastfeed screen positive pregnancy test If sexually active female , surgically sterile least 2 year postmenopausal , agree utilize effective method contraception screen visit least 4 week completion study treatment . History alcohol narcotic substance abuse â‰¤1 year screening . Has dementia another psychiatric illness prevents provision inform consent . Has know hypersensitivity study treatment ( ) , base know allergy drug class include rimantadine HCl memantine HCl . Has participate study involve investigational drug surgery within last 30 day investigational biologics within last 6 month prior screen . Plans undergo major elective surgery course study . Received administration Live Attenuated Influenza Vaccine ( LAIV ) within 2 week . Cognitive impairment , evidence score &lt; 26 Montreal Cognitive Assessment ( MoCA ) screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Levodopa Induced Dyskinesia ( LID )</keyword>
	<keyword>LID</keyword>
	<keyword>Parkinsonism</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>